manilatimes

MEDIPOST's CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

MEDIPOST (CEO Wonil Oh), a global leader in stem cell biotherapeutics, announced today that the Japan Phase 3 clinical trial of its knee osteoarthritis treatment CARTISTEM® achieved statistical ...
Kosmo

MEDIPOST’s CARTISTEM® Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

MEDIPOST (CEO Wonil Oh), a global leader in stem cell biotherapeutics, announced today that the Japan Phase 3 clinical trial of its knee osteoarthritis treatment CARTISTEM ® achieved statistical ...
Finanznachrichten

MEDIPOST's CARTISTEM Meets All Primary and Secondary Endpoints in Japan Phase 3 Trial and Demonstrates Statistically Significant Efficacy Gains Versus Active Control

- Achieved statistical significance versus standard-of-care (SOC) control across all key efficacy endpoints in the 52-week study - Japan Phase 3 results strengthen CARTISTEM's® global commercial ...